 Jeffrey Olson
Concepts (319)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitreous Body | 14 | 2020 | 101 | 3.030 |
Why?
| | Ophthalmologic Surgical Procedures | 5 | 2017 | 57 | 2.220 |
Why?
| | Angiogenesis Inhibitors | 11 | 2022 | 214 | 2.030 |
Why?
| | Retina | 11 | 2016 | 263 | 1.760 |
Why?
| | Glaucoma | 4 | 2017 | 202 | 1.650 |
Why?
| | Alloys | 4 | 2013 | 30 | 1.630 |
Why?
| | Eye Foreign Bodies | 5 | 2016 | 23 | 1.620 |
Why?
| | Macular Edema | 4 | 2022 | 34 | 1.570 |
Why?
| | Retinal Detachment | 6 | 2019 | 53 | 1.540 |
Why?
| | Vitrectomy | 7 | 2019 | 57 | 1.500 |
Why?
| | Diabetic Retinopathy | 6 | 2019 | 149 | 1.490 |
Why?
| | Glaucoma Drainage Implants | 3 | 2016 | 47 | 1.420 |
Why?
| | Retinal Diseases | 5 | 2017 | 76 | 1.280 |
Why?
| | Intraocular Pressure | 7 | 2017 | 276 | 1.260 |
Why?
| | Nanopores | 2 | 2020 | 4 | 1.230 |
Why?
| | Intravitreal Injections | 7 | 2022 | 45 | 1.200 |
Why?
| | Membranes, Artificial | 2 | 2020 | 65 | 1.190 |
Why?
| | Nanotechnology | 2 | 2020 | 113 | 1.120 |
Why?
| | Suction | 3 | 2015 | 31 | 1.030 |
Why?
| | Sutures | 3 | 2015 | 50 | 0.990 |
Why?
| | Choroidal Neovascularization | 4 | 2011 | 44 | 0.970 |
Why?
| | Anterior Eye Segment | 2 | 2017 | 9 | 0.970 |
Why?
| | Swine | 10 | 2017 | 700 | 0.950 |
Why?
| | Suture Techniques | 3 | 2015 | 115 | 0.950 |
Why?
| | Equipment Design | 6 | 2017 | 508 | 0.910 |
Why?
| | Lens Implantation, Intraocular | 2 | 2015 | 57 | 0.890 |
Why?
| | Retinitis | 1 | 2022 | 17 | 0.820 |
Why?
| | Retinal Vasculitis | 1 | 2022 | 7 | 0.820 |
Why?
| | Aneurysm | 1 | 2022 | 29 | 0.800 |
Why?
| | Antibodies, Monoclonal | 6 | 2020 | 1262 | 0.770 |
Why?
| | Vitreoretinopathy, Proliferative | 2 | 2019 | 10 | 0.750 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2020 | 498 | 0.740 |
Why?
| | Immunosuppressive Agents | 3 | 2013 | 646 | 0.720 |
Why?
| | Disease Models, Animal | 8 | 2020 | 3531 | 0.710 |
Why?
| | Retinal Vessels | 2 | 2015 | 50 | 0.710 |
Why?
| | Durapatite | 1 | 2020 | 31 | 0.710 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 17 | 0.690 |
Why?
| | Complement System Proteins | 2 | 2020 | 282 | 0.690 |
Why?
| | Isoxazoles | 2 | 2013 | 51 | 0.680 |
Why?
| | Eye Injuries, Penetrating | 3 | 2016 | 17 | 0.680 |
Why?
| | Endophthalmitis | 2 | 2017 | 25 | 0.680 |
Why?
| | Scleral Buckling | 3 | 2012 | 18 | 0.680 |
Why?
| | Stents | 2 | 2013 | 475 | 0.650 |
Why?
| | Fluorocarbons | 2 | 2012 | 94 | 0.600 |
Why?
| | Glucocorticoids | 2 | 2020 | 532 | 0.570 |
Why?
| | Anterior Chamber | 1 | 2017 | 19 | 0.570 |
Why?
| | Transducers | 1 | 2017 | 25 | 0.570 |
Why?
| | Strabismus | 1 | 2017 | 26 | 0.560 |
Why?
| | Sclera | 2 | 2015 | 35 | 0.540 |
Why?
| | Filtering Surgery | 1 | 2016 | 22 | 0.540 |
Why?
| | Trabeculectomy | 1 | 2017 | 65 | 0.530 |
Why?
| | Surgical Instruments | 2 | 2013 | 47 | 0.530 |
Why?
| | Fovea Centralis | 2 | 2006 | 8 | 0.520 |
Why?
| | Laser Therapy | 1 | 2017 | 100 | 0.510 |
Why?
| | Retinal Perforations | 2 | 2005 | 12 | 0.510 |
Why?
| | Ocular Hypertension | 1 | 2016 | 61 | 0.510 |
Why?
| | Drug Resistance, Multiple, Viral | 2 | 2013 | 11 | 0.510 |
Why?
| | Ophthalmology | 2 | 2013 | 77 | 0.500 |
Why?
| | Lenses, Intraocular | 1 | 2015 | 42 | 0.490 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 249 | 0.490 |
Why?
| | Tomography, Optical Coherence | 7 | 2015 | 130 | 0.490 |
Why?
| | Lasers | 1 | 2015 | 121 | 0.480 |
Why?
| | Device Removal | 1 | 2016 | 126 | 0.480 |
Why?
| | Antiviral Agents | 2 | 2013 | 645 | 0.470 |
Why?
| | Prostheses and Implants | 1 | 2016 | 137 | 0.470 |
Why?
| | Ischemia | 2 | 2017 | 362 | 0.460 |
Why?
| | Fluorescein Angiography | 9 | 2012 | 102 | 0.460 |
Why?
| | Animals | 18 | 2020 | 31694 | 0.460 |
Why?
| | Rabbits | 3 | 2020 | 733 | 0.450 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 178 | 0.440 |
Why?
| | Retinal Degeneration | 2 | 2015 | 30 | 0.440 |
Why?
| | Artificial Lens Implant Migration | 1 | 2013 | 3 | 0.430 |
Why?
| | Choroid | 3 | 2015 | 47 | 0.430 |
Why?
| | Macular Degeneration | 6 | 2015 | 152 | 0.430 |
Why?
| | Viscosupplements | 1 | 2012 | 10 | 0.420 |
Why?
| | Gravitation | 1 | 2012 | 20 | 0.420 |
Why?
| | Silicone Oils | 1 | 2012 | 26 | 0.410 |
Why?
| | Silicon | 1 | 2012 | 13 | 0.410 |
Why?
| | Pupil Disorders | 1 | 2012 | 5 | 0.410 |
Why?
| | Viremia | 1 | 2013 | 122 | 0.410 |
Why?
| | Eye Enucleation | 1 | 2012 | 12 | 0.410 |
Why?
| | Iris | 1 | 2012 | 19 | 0.410 |
Why?
| | Quantum Dots | 1 | 2012 | 35 | 0.400 |
Why?
| | Silicone Elastomers | 1 | 2012 | 7 | 0.400 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 138 | 0.400 |
Why?
| | Uveitis, Posterior | 1 | 2012 | 12 | 0.400 |
Why?
| | Surgical Stapling | 1 | 2012 | 9 | 0.400 |
Why?
| | Fluocinolone Acetonide | 1 | 2012 | 16 | 0.390 |
Why?
| | Electric Stimulation Therapy | 1 | 2012 | 56 | 0.390 |
Why?
| | Vitreous Hemorrhage | 2 | 2015 | 6 | 0.390 |
Why?
| | Cataract Extraction | 1 | 2013 | 76 | 0.390 |
Why?
| | Models, Biological | 4 | 2015 | 1620 | 0.380 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2011 | 61 | 0.380 |
Why?
| | Humans | 47 | 2022 | 114623 | 0.360 |
Why?
| | Oxygen | 1 | 2015 | 854 | 0.350 |
Why?
| | Materials Testing | 1 | 2012 | 337 | 0.350 |
Why?
| | Cytomegalovirus | 2 | 2013 | 144 | 0.350 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 447 | 0.310 |
Why?
| | Biocompatible Materials | 1 | 2012 | 369 | 0.300 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 254 | 0.300 |
Why?
| | Electroretinography | 5 | 2016 | 40 | 0.290 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 11 | 0.280 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2015 | 663 | 0.280 |
Why?
| | Injections | 5 | 2012 | 159 | 0.280 |
Why?
| | Pigment Epithelium of Eye | 2 | 2006 | 34 | 0.270 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.270 |
Why?
| | Drug Implants | 2 | 2020 | 70 | 0.270 |
Why?
| | Recombinant Fusion Proteins | 4 | 2022 | 616 | 0.270 |
Why?
| | Uveal Diseases | 1 | 2006 | 5 | 0.270 |
Why?
| | Ocular Hypotension | 1 | 2006 | 10 | 0.260 |
Why?
| | Female | 26 | 2022 | 59466 | 0.260 |
Why?
| | Fusobacterium Infections | 1 | 2006 | 6 | 0.260 |
Why?
| | Dementia | 2 | 2022 | 187 | 0.260 |
Why?
| | Pharyngeal Diseases | 1 | 2006 | 12 | 0.260 |
Why?
| | Needles | 2 | 2017 | 49 | 0.260 |
Why?
| | Epiretinal Membrane | 1 | 2005 | 6 | 0.260 |
Why?
| | Visual Acuity | 7 | 2019 | 274 | 0.260 |
Why?
| | Ciliary Body | 1 | 2006 | 33 | 0.260 |
Why?
| | Telangiectasis | 1 | 2005 | 6 | 0.260 |
Why?
| | Rats, Inbred BN | 3 | 2011 | 52 | 0.250 |
Why?
| | Uveitis | 1 | 2006 | 115 | 0.250 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 3 | 2022 | 103 | 0.240 |
Why?
| | Kidney Transplantation | 2 | 2013 | 541 | 0.240 |
Why?
| | Middle Aged | 17 | 2019 | 26719 | 0.240 |
Why?
| | Injections, Intraocular | 2 | 2015 | 10 | 0.230 |
Why?
| | Polypropylenes | 2 | 2015 | 14 | 0.230 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 382 | 0.210 |
Why?
| | Laser Coagulation | 3 | 2012 | 54 | 0.210 |
Why?
| | Bevacizumab | 6 | 2015 | 115 | 0.210 |
Why?
| | Optic Atrophy | 1 | 2022 | 10 | 0.210 |
Why?
| | Hearing Loss, Central | 1 | 2022 | 5 | 0.210 |
Why?
| | Rats | 4 | 2012 | 4958 | 0.200 |
Why?
| | Retinal Vein Occlusion | 2 | 2015 | 13 | 0.190 |
Why?
| | Cell Count | 2 | 2012 | 303 | 0.190 |
Why?
| | Male | 21 | 2019 | 55554 | 0.180 |
Why?
| | Dialysis | 1 | 2020 | 17 | 0.180 |
Why?
| | Adult | 11 | 2022 | 30528 | 0.180 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2000 | 10 | 0.180 |
Why?
| | Orbital Neoplasms | 1 | 2000 | 21 | 0.180 |
Why?
| | Time Factors | 4 | 2017 | 6112 | 0.180 |
Why?
| | Follow-Up Studies | 5 | 2015 | 4411 | 0.180 |
Why?
| | Adsorption | 1 | 2020 | 119 | 0.170 |
Why?
| | Biomarkers | 2 | 2020 | 3408 | 0.170 |
Why?
| | Wet Macular Degeneration | 1 | 2019 | 32 | 0.160 |
Why?
| | Geographic Atrophy | 1 | 2019 | 49 | 0.160 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 37 | 0.150 |
Why?
| | Eye Diseases, Hereditary | 1 | 2018 | 11 | 0.150 |
Why?
| | Miniaturization | 2 | 2015 | 23 | 0.150 |
Why?
| | Hypertension | 1 | 2006 | 1056 | 0.150 |
Why?
| | Dextrans | 2 | 2009 | 73 | 0.150 |
Why?
| | Iris Diseases | 1 | 2017 | 5 | 0.140 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 797 | 0.140 |
Why?
| | Choroid Diseases | 1 | 2017 | 9 | 0.140 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 1997 | 13 | 0.140 |
Why?
| | Aged, 80 and over | 6 | 2019 | 6344 | 0.140 |
Why?
| | Dark Adaptation | 2 | 2012 | 13 | 0.140 |
Why?
| | Antimony | 1 | 2016 | 4 | 0.140 |
Why?
| | Aged | 10 | 2020 | 19061 | 0.140 |
Why?
| | Infliximab | 2 | 2007 | 94 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 1842 | 0.140 |
Why?
| | Polymers | 1 | 2020 | 448 | 0.130 |
Why?
| | Treatment Outcome | 9 | 2016 | 9084 | 0.130 |
Why?
| | Pressure | 1 | 2017 | 214 | 0.130 |
Why?
| | Sclerostomy | 1 | 2015 | 4 | 0.130 |
Why?
| | Foreign-Body Migration | 1 | 2016 | 37 | 0.130 |
Why?
| | Gyrate Atrophy | 1 | 2015 | 2 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2014 | 1183 | 0.130 |
Why?
| | Down Syndrome | 1 | 2000 | 335 | 0.130 |
Why?
| | Vitreoretinal Surgery | 1 | 2015 | 3 | 0.120 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 26 | 0.120 |
Why?
| | Stress, Mechanical | 1 | 2017 | 445 | 0.120 |
Why?
| | Vitreous Detachment | 1 | 2015 | 5 | 0.120 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 36 | 0.120 |
Why?
| | Equipment Failure Analysis | 1 | 2015 | 132 | 0.120 |
Why?
| | Partial Pressure | 1 | 2015 | 30 | 0.120 |
Why?
| | Hemoglobin SC Disease | 1 | 2015 | 15 | 0.120 |
Why?
| | Feedback | 1 | 2015 | 144 | 0.120 |
Why?
| | Biopsy, Needle | 1 | 2015 | 182 | 0.120 |
Why?
| | Prosthesis Failure | 1 | 2016 | 115 | 0.120 |
Why?
| | Protein Binding | 1 | 2020 | 1889 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2014 | 40 | 0.120 |
Why?
| | International Normalized Ratio | 1 | 2014 | 45 | 0.120 |
Why?
| | Postoperative Care | 1 | 2015 | 222 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2012 | 2094 | 0.110 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2013 | 15 | 0.110 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1016 | 0.110 |
Why?
| | Retinal Artery Occlusion | 1 | 2013 | 8 | 0.110 |
Why?
| | Warfarin | 1 | 2014 | 135 | 0.110 |
Why?
| | Metabolomics | 1 | 2018 | 521 | 0.110 |
Why?
| | Tendons | 1 | 2014 | 120 | 0.110 |
Why?
| | Research Design | 1 | 2019 | 928 | 0.110 |
Why?
| | Specific Gravity | 1 | 2012 | 11 | 0.110 |
Why?
| | Transducers, Pressure | 1 | 2012 | 13 | 0.110 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 1879 | 0.110 |
Why?
| | Erythrocyte Transfusion | 1 | 2015 | 189 | 0.110 |
Why?
| | Adaptation, Ocular | 1 | 2012 | 4 | 0.100 |
Why?
| | Minerals | 1 | 2012 | 37 | 0.100 |
Why?
| | Rats, Mutant Strains | 1 | 2012 | 25 | 0.100 |
Why?
| | Viscosity | 1 | 2012 | 81 | 0.100 |
Why?
| | Adolescent | 4 | 2019 | 17831 | 0.100 |
Why?
| | Pupil | 1 | 2012 | 13 | 0.100 |
Why?
| | Acetates | 1 | 2012 | 95 | 0.100 |
Why?
| | Corneal Endothelial Cell Loss | 1 | 2012 | 2 | 0.100 |
Why?
| | Retinal Neovascularization | 1 | 2012 | 20 | 0.100 |
Why?
| | Endothelium, Corneal | 1 | 2012 | 15 | 0.100 |
Why?
| | Sodium Chloride | 1 | 2012 | 136 | 0.100 |
Why?
| | Electrodes, Implanted | 1 | 2012 | 91 | 0.100 |
Why?
| | Drug Combinations | 1 | 2012 | 287 | 0.100 |
Why?
| | Swine, Miniature | 1 | 2012 | 71 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2007 | 1139 | 0.100 |
Why?
| | Microsurgery | 1 | 2012 | 59 | 0.100 |
Why?
| | Retinal Ganglion Cells | 1 | 2012 | 92 | 0.100 |
Why?
| | Gold | 1 | 2012 | 106 | 0.100 |
Why?
| | Bruch Membrane | 1 | 2011 | 6 | 0.100 |
Why?
| | Registries | 1 | 2019 | 1767 | 0.090 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 43 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 728 | 0.090 |
Why?
| | Drug Compounding | 1 | 2011 | 89 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2015 | 12542 | 0.090 |
Why?
| | Computer Simulation | 1 | 2015 | 872 | 0.090 |
Why?
| | Atrial Fibrillation | 1 | 2014 | 322 | 0.090 |
Why?
| | Dissection | 1 | 2011 | 51 | 0.090 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 159 | 0.090 |
Why?
| | Anemia, Sickle Cell | 1 | 2013 | 215 | 0.090 |
Why?
| | Models, Animal | 1 | 2012 | 344 | 0.090 |
Why?
| | Lactic Acid | 1 | 2011 | 275 | 0.080 |
Why?
| | Bacteria | 1 | 2015 | 725 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1020 | 0.080 |
Why?
| | Scotoma | 1 | 2008 | 4 | 0.080 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2007 | 49 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2537 | 0.070 |
Why?
| | Pilot Projects | 1 | 2012 | 1372 | 0.070 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2007 | 30 | 0.070 |
Why?
| | Papilledema | 1 | 2007 | 40 | 0.070 |
Why?
| | Visual Fields | 3 | 2007 | 77 | 0.070 |
Why?
| | Young Adult | 2 | 2019 | 10455 | 0.070 |
Why?
| | RNA, Catalytic | 1 | 2007 | 182 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 16 | 0.070 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2006 | 22 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 561 | 0.070 |
Why?
| | Triamcinolone Acetonide | 1 | 2006 | 27 | 0.070 |
Why?
| | Fusobacterium necrophorum | 1 | 2006 | 1 | 0.070 |
Why?
| | Indocyanine Green | 1 | 2005 | 12 | 0.070 |
Why?
| | Myopia | 1 | 2006 | 36 | 0.060 |
Why?
| | Vision, Low | 3 | 2013 | 14 | 0.060 |
Why?
| | Coloring Agents | 1 | 2005 | 72 | 0.060 |
Why?
| | Eye Injuries | 1 | 2006 | 44 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 371 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2005 | 134 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 333 | 0.060 |
Why?
| | Cataract | 1 | 2006 | 185 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1430 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1342 | 0.050 |
Why?
| | Ranibizumab | 2 | 2013 | 18 | 0.050 |
Why?
| | Blindness | 2 | 2013 | 37 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2012 | 2128 | 0.050 |
Why?
| | Keratitis | 1 | 2000 | 11 | 0.040 |
Why?
| | Exophthalmos | 1 | 2000 | 19 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1578 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2000 | 274 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2279 | 0.040 |
Why?
| | Xanthine | 1 | 2018 | 7 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1121 | 0.040 |
Why?
| | Electrooculography | 1 | 1997 | 10 | 0.040 |
Why?
| | Visual Field Tests | 1 | 1997 | 13 | 0.040 |
Why?
| | Color Vision Defects | 1 | 1997 | 6 | 0.040 |
Why?
| | Fundus Oculi | 1 | 1997 | 40 | 0.040 |
Why?
| | Purines | 1 | 2018 | 159 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 4894 | 0.040 |
Why?
| | Child | 2 | 2015 | 18404 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 953 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1997 | 203 | 0.030 |
Why?
| | Vision Disorders | 1 | 1997 | 130 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 29 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 111 | 0.030 |
Why?
| | Myopia, Degenerative | 1 | 2015 | 3 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 282 | 0.030 |
Why?
| | Endotamponade | 1 | 2015 | 4 | 0.030 |
Why?
| | Pregnancy | 1 | 2007 | 5517 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2380 | 0.030 |
Why?
| | Tissue Adhesions | 1 | 2015 | 26 | 0.030 |
Why?
| | Tenon Capsule | 1 | 2014 | 3 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 633 | 0.030 |
Why?
| | Photography | 1 | 2015 | 88 | 0.030 |
Why?
| | Atrophy | 1 | 2015 | 152 | 0.030 |
Why?
| | Biometry | 1 | 2014 | 62 | 0.030 |
Why?
| | Conjunctiva | 1 | 2014 | 51 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 8628 | 0.030 |
Why?
| | Glucose | 1 | 2018 | 896 | 0.030 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2014 | 122 | 0.030 |
Why?
| | Risk Assessment | 2 | 2014 | 2967 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2018 | 1076 | 0.020 |
Why?
| | Retreatment | 1 | 2012 | 67 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 811 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 287 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1075 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 2796 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1211 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 381 | 0.020 |
Why?
| | Antioxidants | 1 | 2014 | 530 | 0.020 |
Why?
| | Anticoagulants | 1 | 2014 | 550 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 373 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1448 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2009 | 59 | 0.020 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2009 | 45 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4099 | 0.020 |
Why?
| | Prospective Studies | 2 | 2012 | 6217 | 0.020 |
Why?
| | Retinal Artery | 1 | 2007 | 15 | 0.020 |
Why?
| | Infant | 1 | 2000 | 7959 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2007 | 109 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3328 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2006 | 26 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 27 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1477 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2007 | 222 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 497 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2007 | 1660 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2552 | 0.010 |
Why?
| | Aging | 1 | 2008 | 1618 | 0.010 |
Why?
|
|
Olson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|